Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-08
2005-11-08
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S455000, C514S461000, C514S777000, C514S937000, C514S941000, C514S970000
Reexamination Certificate
active
06962944
ABSTRACT:
Beta-lapachone, which is poorly soluble in most pharmaceutically acceptable solvents, has demonstrated significant antineoplastic activity against human cancer lines. The present invention overcomes this significant limitation by teaching novel pharmaceutical compositions comprising a therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier molecule, which may be at water-solubilizing carrier molecule such as hydroxypropyl-β-cyclodextrin, or an oil-based solubilizing carrier molecule, for enhancing the solubility of Beta-lapachone in aqueous solution. The therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, may be complexed with the pharmaceutically acceptable solubilizing carrier molecule in aqueous solution. The novel pharmaceutical compositions may be administered with a second anticancer agent or in combination with radiation therapy. A formulation of Beta-lapachone or a derivative or analog thereof, complexed with a pharmaceutically acceptable solubilizing carrier molecule, wherein the complex can be freeze-dried and when subsequently reconstituted in aqueous solution is substantially soluble is also disclosed. Emulsions of Beta-Lapachone in a pharmaceutically acceptable fat emulsion vehicle are also provided. Also disclosed are methods for treating cancer by administering to a patient the novel pharmaceutical compositions and formulations. Pharmaceutical kits are also provided.
REFERENCES:
patent: 2827452 (1958-03-01), Schlenk
patent: 3453259 (1969-07-01), Parmerter et al.
patent: 3459731 (1969-08-01), Gramera et al.
patent: 4371673 (1983-02-01), Pitha
patent: 4380626 (1983-04-01), Szejtli et al.
patent: 4383992 (1983-05-01), Lipari
patent: 4524068 (1985-06-01), Szejtli et al.
patent: 4542211 (1985-09-01), Szejtli et al.
patent: 4555504 (1985-11-01), Jones
patent: 4582900 (1986-04-01), Brandt et al.
patent: 4596795 (1986-06-01), Pitha
patent: 4638058 (1987-01-01), Brandt et al.
patent: 4727064 (1988-02-01), Pitha
patent: 4983586 (1991-01-01), Bodor
patent: 5763625 (1998-06-01), Boothman et al.
patent: 5824700 (1998-10-01), Frydman et al.
patent: 5969163 (1999-10-01), Frydman et al.
patent: 6245807 (2001-06-01), Pardee et al.
patent: 6407079 (2002-06-01), Muller et al.
patent: 33 45 780.8 (1983-12-01), None
patent: 33 46 123.6 (1985-06-01), None
patent: 0184990 (1986-06-01), None
patent: 0 149 197 (1990-03-01), None
patent: 0 119 543 (1990-06-01), None
patent: 2 484 252 (1981-12-01), None
patent: 57126802 (1982-08-01), None
patent: 57200361 (1982-12-01), None
patent: 58144376 (1983-08-01), None
patent: WO 82/00251 (1982-02-01), None
patent: WO 85/02767 (1985-07-01), None
patent: WO 94/04145 (1994-03-01), None
patent: WO 96/11005 (1996-04-01), None
patent: WO 97/31936 (1997-09-01), None
patent: WO 00/61142 (2000-10-01), None
patent: WO 01/64214 (2001-09-01), None
patent: WO 03/090710 (2003-11-01), None
Nasongkla et al., Pharm Res. 20(10):1626-1633. 2003.
Stella and Rajewski , Pharm Res. 14(5):556-567, 1997.
Szejtli, Chem Rev. 98(5):1743-1754, 1998.
Loftsson and Brewster, J Pharm Sci. 85(10):1017-1025, 1996.
Rajewski and Stell, J Pharm Sci. 85(11):1142-1169, 1996.
Irie and Uekama, J Pharm Sci. 86(2):147-162, 1997.
Rekharsky and Inoue, Chem Rev. 98(5):1875-1918, 1998.
Wuerzberger et al., Cancer Res. 58(9):1876-1885, 1998.
Tagliarino et al., J Biol Chem. 276(22):19150-19159, 2001.
Planchon, et al. (1996).Cancer Res. 55: 3706-3711.
Li, et al. (1995).Cancer Res. 55: 3712-3715.
Weller , et al. (1997).Int. J. Cancer73: 707-714.
Lai, et al. (1998).Histol. Histophathol. 13: 89-97.
Huang, et al. (1999).Mol. Med. 5: 711-720.
Wuerzberger, et al. (1998).Cancer Res. 58: 1876-1885.
Li, et al. (1999).Proc. Natl. Acad. Sci. USA96(23): 13369-13374.
Li, et al. (2000).Mol. Med. 6: 1008-1015.
Li, et al. (1999).Mol. Med. 5: 232-239.
Boothman, et al. (1987).Cancer Res. 47: 5361-5366.
Boorstein and Pardee (1983).Biochem Biophys. Commun. 117(1): 30-36.
Schaffner-Sabba, et al. (1984).J. Med. Chem. 27: 990-994.
Sun, et al. (1998).Tetrahedron Letters39: 8221-8224.
Amaral, et al. (1992).J. Heterocyclic Chem. 29(6): 1457-1460.
Li, et al. (1993).J. Biol. Chem. 268(30): 22463-22468.
Portela and Stoppani (1996).Biochem Pharm51: 275-283.
Goncalves, et al. (1980).Mol. and Biochem Parasitology1: 167-176.
Frydman, et al. (1997).Cancer Res. 57: 620-627.
Krishnan and Bastow (2000).Biochem Pharm60: 1367-1379.
Pink, et al. (2000).J. Biol. Chem. 275(8): 5416-.
Maruyama and Naruta. (1977).Chem Lett. pp. 847-850.
Szejtli (1982). Chinoin Res Cent Biochem Res Lab, Budapest, Hungary: 204-232.
Croft and Bartsch (1983). Tetrahedron 39: 1417-1474.
Fenyvesi, et al. (1981). Int Symp Cyclodextrins, Budapest, Hungary: 345-356.
Szejtli, et al. (1980). Starke 32, 165.
Szejtli, et al. (1980). Starch 32: 165-169.
Jiang Zhiwei
Reddy Dasharatha G.
Arqule Inc.
Elriti Ivor
Krass Frederick
Lewis Amy
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
LandOfFree
Pharmaceutical compositions containing beta-lapachone, or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions containing beta-lapachone, or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions containing beta-lapachone, or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3477444